Effect of Concomitant Ingestion of Alcohol on the In Vivo Pharmacokinetics of KADIAN (Morphine Sulfate Extended-Release) Capsules

Journal of Pain

Volumn 9, Issue 4, 2008, Pages 330-336

  Johnson, Franklin ^a   Wagner, George ^a   Sun, Stephen ^a   Stauffer, Joseph ^a  

^a Alpharma Pharmaceuticals LLC   (United States)

Author keywords

alcohol; KADIAN; morphine sulfate extended release; naltrexone; opioid; pharmacokinetics

Indexed keywords

ALCOHOL; MORPHINE SULFATE; NALTREXONE; WATER;

ADULT; ALCOHOL CONSUMPTION; ANALYSIS OF VARIANCE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ALCOHOL INTERACTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG SAFETY; DRUG WITHDRAWAL; HEADACHE; HUMAN; IN VIVO STUDY; MALE; NORMAL HUMAN; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOMNOLENCE; THORAX PAIN; VOMITING;

ADMINISTRATION, ORAL; ADULT; ANALGESICS, OPIOID; BIOLOGICAL AVAILABILITY; CAPSULES; CENTRAL NERVOUS SYSTEM DEPRESSANTS; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG SYNERGISM; DRUG TOXICITY; ETHANOL; HUMANS; MALE; MORPHINE; PAIN;

EID: 40949124838     PISSN: 15265900     EISSN: 15288447     Source Type: Journal    
DOI: 10.1016/j.jpain.2007.11.009     Document Type: Article

References (20)

1. American Pharmacists Association. Palladone Capsules New Product Bulletin (2004), American Pharmacists Association, Washington, DC
2. AVINZA [package insert] (2006), King Pharmaceuticals, Inc, Bristol, TN
3. Gourlay G.K. Sustained relief of chronic pain: Pharmacokinetics of sustained release morphine. Clin Pharmacokinet 35 (1998) 173-190
4. KADIAN [package insert] (2007), Alpharma Pharmaceuticals LLC, Piscataway, NJ
5. Ligand Pharmaceuticals Inc. Dear Health Care Professional Letter (2005), Ligand Pharmaceuticals Inc
6. Meyer R.J., and Hussain A.S. Awareness Topic: Mitigating the Risks of Ethanol Induced Dose Dumping from Oral Sustained/Controlled Release Dosage Forms (2005) FDA Advisory Committee for Pharmaceutical Services Meeting
7. MS Contin [package insert] (2005), Purdue Pharma LP, Stamford, CT
8. OPANA ER [package insert] (2007), Endo Pharmaceuticals Inc, Chadds Ford, PA
9. Oramorph SR [package insert] (2005), aaiPharma Inc, Wilmington, NC
10. Oxycodone hydrochloride extended-release tablets [package insert] (2004), Endo Pharmaceuticals Inc, Chadds Ford, PA
11. Reder R.F. Opioid formulations: Tailoring to the needs in chronic pain. Eur J Pain 5 Suppl A (2001) 109-111
12. Substance Abuse and Mental Health Services Administration, and Office of Applied Studies. Drug Abuse Warning Network, 2005: National Estimates of Drug-Related Emergency Department Visits (2007) Rockville, MD. DAWN Series D-29, DHHS Publication No. (SMA) 07-4256
13. US Department of Health and Human Services, and Substance Abuse and Mental Health Services Administration Office of Applied Studies. National Survey on Drug Use and Health (NSDUH) (2005), US Department of Health and Human Services Substance Abuse and Mental Health Services Administration Office of Applied Studies
14. US Food and Drug Administration. Palladone (Hydromorphone Hydrochloride Extended-Release) Capsules: Questions and Answers (2005), US Food and Drug Administration
15. US Food and Drug Administration. Letter to Alpharma Pharmaceuticals NDA 20-616/S-017 and S-021. 2-27-2007. Rockville, MD, US Food and Drug Administration
16. US Food and Drug Administration, and Center for Biologics Evaluation and Research. Guidance for Industry: In Vivo Drug Metabolism/Drug Interaction Studies-Study Design, Data Analysis, and Recommendations for Dosing and Labeling (1999), US Food and Drug Administration, Center for Biologics Evaluation and Research
17. US Food and Drug Administration, and Center for Drug Evaluation and Research. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations (2007), US Food and Drug Administration, Center for Drug Evaluation and Research
18. US Food and Drug Administration, and Center for Drug Evaluation and Research. Guidance for Industry: Food-Effect Bioavailability and Fed Bioequivalence Studies (2002), US Food and Drug Administration, Center for Drug Evaluation and Research
19. US Food and Drug Administration. FDA Alert: Alcohol-Palladone Interaction. Alert for Healthcare Professionals: Hydromorphone hydrochloride extended-release capsules. 7-13-2005. US Food and Drug Administration. 2-23-2007
20. Weathermon R., and Crabb D.W. Alcohol and medication interactions. Alcohol Res Health 23 (1999) 40-54